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INTRODUCTION 
Exposure of a host to a foreign antigen elicits an immune response 
in which specific immunoglobulins and effector lymphocytes are produced 
to identify and neutralize this foreign substance. Elimination and des-
truction of the identified antigen proceeds through the functional limb 
of the immune system, which includes immune effectors (complement, kinin, 
coagulation, lymphokines, and lymphotoxin). On activation of an immune 
response, an inflammatory reaction is a result of the release of bio-
logically active products from the immune effector systems. Generally, 
these products cause increased vascular permeability, smooth muscle con-
traction, and chemotaxis of leukocytes. In the ensuing response, leuko-
cytic phagocytosis functions as the major defense mechanism for the re-
moval and degradation of antigens. In many bacterial infections, a hu-
moral response facilitates this phagocytosis through the production of 
agglutinating and opsonizing antibodies, and by the amplification of the 
inflammatory response through complement activation. However, in many 
respects the biosynthesis of antibodies is too slow and ponderous a mech-
anism for the purposes of host defense. Therefore,initial biological re-
sponse at a local site of infection does not rely on a de novo immune reac-
tion, but on innate (nonspecific activation of effectors) mechanisms that 
trigger inflammation and enhance phagocytosis. Both innate and immune 
mechanisms in host defense have been reviewed (Humphrey and White, 1970; 
and Davis et al., 1973). 
1 
A variety of microbial factors and products cause potent biologi-
cal changes in a host through initial and prolonged exposure. Complement 
(an alternate pathway) has been implicated as a humoral effector system 
in reactions with microbial factors such as bacterial polysaccharides, 
yeast cell walls, Gram-negative bacteria, and the endotoxic lipopolysac-
charide (LPS) of certain Gram-negative species (Gotze and Muller-Eber-
hard, 1976). The activation of complement by endotoxin has been implicated 
as a potential pathologic factor in specialized tissues which are suscep-
tible to damage by inflannnatory products (Mergenhagen et al., 1968; Gewurz 
et al., 1971; and Synderman 1972b). These pathological conditions include 
both acute and chronic inflammation in tissues such as the glomerulus and 
periodontium. The presence of immunoglobulins to antigens, including endo-
toxin, have to be considered together with innate inflammatory mechanisms. 
The participation of an endotoxin-activated complement system, in the pres-
ence or absence of an immune response to this antigen in generating biolog-
ical activity is undefined. 
2 
The objective of this study is to compare in vitro complement genera-
ted chemotaxis in an immune system to chemotaxis in non-immune LPS-comple-
ment activation. This comparison of chemotactic activity in two functional 
complement pathways (immune system) to the alternate pathway (non-immune 
activation), solely, will be related to in vivo LPS-complement participation 
in inflammation and destruction in specialized tissues. 
REVIEW OF THE LITERATURE 
Endotoxic lipopolysaccharides and Gram-negative bacterial cells caused 
potent biological reactions when injected into experimental animals. The 
activation of a histamine-releasing factor through a heat-labile serum en-
zyme has been implicated as the cause of the major physiological changes 
of endotoxin: shock, fever, local inflammatory skin reactions, and death 
(Greisman, 1960; Spink and Vick, 1961; and Weil and Spink, 1957).Comple-
ment activation was implicated in these in vivo reactions when all the 
major physiological changes due to the presence of endotoxin were repro-
duced in laboratory animals by employing immune complexes (Stetson, 1964). 
In addition, complement-induced anaphylactic shock was shown to simulate 
endotoxin shock (Weil and Spink, 1957). LPS was further demonstrated to 
cause a significant decline in rabbit serum complement levels following 
the injection of lethal doses (Gilbert and Braude, 1962; and Pearlman et 
al., 1963). In addition, the early phase of endotoxin shock in dogs could 
be prevented by a cobra venom factor (CVF) decomplementation, which im-
plicated the complement system as the mediator (Gewurz et al., 1970). 
The endotoxic lipoplysaccharides of certain Gram-negative bacteria 
have been demonstrated to function as activating factors of both the al-
ternate pathway of complement fixation in immunoglobulin-independent reac-
tions (figure 1), and the classic complement pathway (figure 2) in immuno-
globulin-deperident reactions (Mergenhagen et al., 1973; and Westphal, 1975). 
These two distinct pathways of complement activation have been observed in 
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FIGURE 2 
Classical Complement Activation 
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(modified reproduction from Gewurz et al., 1969) 
normal vertebrate serum, and function in both specific and nonspecific 
reactions in host defense. 
The classical complement sequence is a multimolecular, self-assemb-
ling biological system which constitutes the primary humoral mediator of 
antigen-antibody reactions (Muller-Eberhard, 1975; and Davis et al., 1973). 
Operationally, this pathway can be divided into three functional units: Cl 
(Clq-Clr-Cls), the recognition unit; the activation unit, C2, C3, C4; and 
the membrane attack unit, C5b-C6-C7-C8-C9. The first three components 
function as a ca++- -dependent, trimolecular complex (Cl) which combines re-
versibly with immune complexes of IgG or IgM. The Clq component possesses 
recognition-binding sites for a receptor on the Fe portion of the innnuno-
globulin. Following binding, Clq undergoes conformational change that, in 
turn, activates Clr as an enzyme. Clr then cleaves s small fragment from 
Cls, which activates the remaining fragment as a serine enzyme (Cls). 
The second stage of the classical sequence involves the sequential · 
formation of two related enzymes initiated by Cls. C4 is the natural sub-
strate of Cls, and is cleaved in large amounts into C4a and C4b. The C4b 
fragment can attach to the cell membrane (particle surface), and a small 
percentage becomes bound. The resultant Cls-C4b site has the capacity to 
neutralize certain viruses. In the following step, C2 is adsorbed by mem-
brane-bound C4b (Mg++- -dependent), and is cleaved by Cls into C2a and C2b. 
The C2a fragment fuses with C4b to form another enzyme with C3 as its sub-
strate (C3 convertase), while C2b enters the fluid phase. C4b-C2a then 
cleaves C3 into two fragments, C3a and C3b, allowing nascent C3b to asso-
ciate itself with the activating enzyme. C3a (anaphylatoxin) is given off 
6 
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into the fluid phase, while C3b possesses a transient ability to attach 
and opsonize cell membranes. The latter has a binding site for lympho-
cytes and various phagocytic cells, and functions in immune adherence and 
in enhancing phagocytosis. The further association of C3b with C4b-C2a 
on the membrane surface gives rise to a trimolecular complex with CS-cleav-
ing activity (C4b-C2a-C3b). CS is split into CSa (anaphylatoxin and chemo-
tactic factor), the fluid phase component, and CSb which possesses a tran-
sient binding site. 
The third phase of the classical sequence is initiated by the cleavage 
of CS, which initiates the formation of the stable CSb-C9 complex in both 
the fluid phase and on the active site. CSb sequentially activates, with-
out further enzymatic activation, the attachment of C6 and C7 (chemotactic 
activity) with C8 and six molecules of C9. The complex (CSb-C6-C7-C8-C9) 
has the ability to alter cell membranes and cause irreversible damage. 
The rapid decay of activated binding sites restricts complement action 
I 
to the immediate environment of the site. Rigid control also limits the 
time and space of classical complement reactions by the decay of C4b-C2a 
and C4b-C2a-C3b, and through the actions of serum Cl inactivator and C3b 
inactivator (Muller-Eberhard, 197S; and Mayer, 1970). These classical 
complement reactions have been studied in great detail and recently re-
viewed (Davis et al., 1973; Humphrey and White, 1970; and Muller-Eberhard, 
197S). 
Recent studies have demonstrated that the endotoxins of certain Gram-
negative bacteria function as activating factors of the alternate pathway 
of complement activation. The ability of LPS to deplete complement com-
ponents was first observed to be a function of a newly discovered "prop-
erdin" system. This system was described as a group of normal serum pro-
teins which interacted with zymosan, a variety of polysaccharides, and 
lipopolysaccharide and resulted in the preferential consumption of "C3"* 
in the presence of Mg++(Pillemer et al., 1954, 1955; Wedgwood et al., 1956; 
Wardlaw and Pillemer, 1956; and Hinz et al., 1956). This group of factors 
appeared to mediate several diverse activities of normal serum such as, the 
killing of Gram-negative bacteria, neutralization of certain viruses, and 
lysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinu-
ria (PNH). 
A number of factors have been shown to activate the complement se-
quence without significant consumption of Cl, C2, and C4 (Sandberg et al., 
1970; and Gewurz et al., 1968b). The absence of any reaction of endotoxin 
with each of the terminal components indicated the need for serum factors 
other than Cl, C2 and C4 in complement activation (Gewurz et al., 1968b). 
These results were corroborated by similar experiments that firmly estab-
lished the existence of a second complement pathway. By demonstrating the 
complement consuming ability of guinea pig y-1 antibodies, the ability of 
C4-deficient serum to sustain complement activation, and the C3-cleaving 
activity of LPS in C2-adsorbed guinea pig serum, an alternate pathway was 
believed to exist (Frank et al., 1971; Sandberg et al., 1970, 1971; and 
*C3 was an early designation of components C3 to C9. 
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Marcus et al., 1971). 
Through a second series of related investigations with cobra venom 
factor (CVF), the "C3 activator system" was identified as an alternate 
complement pathway (Muller-Eberhard & Gotze, 1971). Recent investigations 
have identified the properdin and activator systems as an identical path-
way, and has currently led to the postulation of a plausible molecular 
concept of alternate pathway activation (Muller-Eberhard, 1975; and Gotze 
& Muller-Eberhard, 1976). Activation of this pathway has been demonstrated 
to occur through a number of substances including LPS, plant polysacchar-
ides, a number of polymeric substances, T cell-independent antigens, B cell 
mitogens, levan-polymerized flagellin, dextran sulfate, and pokeweed mito-
gen (Mergenhagen et al., 1969, 1973; Burger et al., 1975; Radding et al., 
1973; and Bitter-Suermann et al., 1975). Immunoglobulin activation of the 
alternate pathway is not required, but does occur frequently. Guinea pig 
y-1 and y-2, as well as rabbit IgG, have the ability to activate the alter-
nate pathway through a site in their F(ab') 2 fragment (Burger' et al., 1975; 
Osler et al., 1969; Reid, 1971; Sandberg et al., 1972, 1970, 1971; and 
Schur & Becker, 1963). Aggregates of human IgA1 and IgA2 are endowed with 
the same capacity, while human IgG aquires the function only under excep-
tional circumstances (Gotze & Muller-Eberhard, 1976). 
In a yet unknown manner, an alternate pathway activator causes the 
conversion of the properdin precursor to active properdin (P). However, 
recent evidence indicates that there are several factors that preceed prop-
erdin utilization (table 1) (Muller-Eberhard, 1975). Following the contact 
9 
Table l 
Nomenclature and Proteins of the Properdin System. 
Protein Component 
Initiating Factor 
Properdin 
3rd Complement Component 
C3 Proactivator 
C3 Proactivator Convertase 
C3 I: nact i va tor 
C3 l:nactivator Accelerator 
Symbol 
lF 
p 
C3 
C3Pa,Pa,,orB 
Pase,orO 
C3b INA 
B1H 
Molecular 
Weight 
160-180,000 
212,000 
180,000 
93 ,,000 
24.000 
100,000 
150,000 
(renroduced with modifications from Muller-Eberhard, 1975) 
Serum 
Cone. 
(ug/ml) 
20-50 
25 
1,104-1,373 
143-226 
1-5 
30-50 
133 
I-' 
0 
with essential structures of the activating particle, an activated initia-
ting factor (IF) interacts with Pa (factor B), Pase (factor D), and native 
C3 (in the presence of Mg++) to generate a C3 convertase (figure 1). Pa 
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and C3 interact without enzymatic cleavage and can be recovered intact after 
activation (Fearon & Austen 1975; Nicholson et al., 1975; and Vogt et al., 
1975). This soluble enzyme acts only on C3, and can deposit C3b onto the 
surface of the activating substance. The latter fragment subsequently a-
quires a transient site for various acceptors (Muller-Eberhard, 1966), a 
stable binding site for immune adherence reactions (Eden et al., 1973; Lay 
& Nussenzweig, 1968; and Vogt et al., 1975), a site which interacts with 
Pa and Mg++, and a binding site for activated properdin (Fearon & Austen, 
1975). 
In this initial cleavage of C3, C3b is also deposited in the fluid 
phase (with C3a), which leads to the further formation of a soluble, labile 
C3 convertase and a bound, labile C3-C5 convertase (Gotze & Muller-Eberhard, 
1976). Analogous to classical C4b-C2a, bound and soluble C3b. display a Mg++ 
-dependent affinity for PA in the formation of a reversible inactive complex 
(Medicus et al., 1976; Nicholson et al., 1975, and Vogt et al., 1975, 1976). 
This complex is then subject to the hydrolytic action of Pase, which cleaves 
a fragment from Pa, producing a complex (C3b-Bb) possessing C3-cleaving ac-
tivity (active site on Bb). This convertase has been shown to operate in a 
positive feedback mechanism through the generation of C3b fragments (Muller-
Eberhard & Gotze, 1972; Gotze & Muller-Eberhard, 1976; and Brade et al., 
1974). Evidence suggests that at least two spacially arranged molecules 
12 
are necessary for C3b-Bb expression of CS convertase activity (C3b -Bb, where 
n 
n>l). CS cleavage, as in the classical pathway, activates terminal compo-
nents involved in the membrane attack unit. Both C3 and CS convertase of 
the alternate pathway are analogous to the classical pathway enzymes, and 
function in producing large amounts of biologically active products (C3a 
and CSa) in the fluid phase. 
It is now clear that properdin is utilized in the final steps of this 
pathway. It occurs in serum in a precursor form, and is able to form a 
- ++ P-dependent C3 convertase with Pa, Pase, C3, and Mg (Gotze & Muller-Eber-
hard, 1976). Evidence suggests that surface-bound CS convertase (C3b -Bb) 
n 
is the properdin activating factor, and that P also participates in a fluid 
phase C3 convertase. The attachment of P to the bound CS convertase in-
creases the half-life of the enzyme by conferring stability on the associa-
tion of C3b-B and by retarding spontaneous decay (Fearon & Austen, 197S; 
and Vogt et al., 1974, 1976). The stabilized enzyme (C3b -Bb-P)acts on 
n 
both C3 and CS, and can undergo reverse assembly by loss of factor B. This 
P-bound site can attain enzymatic activity by the reaquisition of B in the 
++ presence of Mg and Pase (factor D). 
This complex pathway has, at present, three known modes of regulation. 
C3-CS convertase decays spontaneously due to the loss of Bb. Secondly, sol-
uble C3b can actively disassemble P-stabilized CS convertase by releasing Bb. 
The third is by the action of a serum enzyme, C3b inactivator (C3b INA), 
which cleaves bound C3b into two smaller fragments, and causes the release 
of bound P (Medicus et al., 1976; and Gotze & Muller-Eberhard, 1976). Op-
timal inhibitory regulation of C3b inactivator requires the simultaneous 
presence of yet another serum protein. The effector is a !Os, S1H-globulin 
(C3b INA accelerator), which operates in trace amounts (Whaley and Ruddy, 
1976; Gitlin et al., 1975; Lachmann and Muller-Eberhard,'1968; and Nilsson 
& Muller-Eberhard, 1965). 
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Thus, through the activation of either complement pathway, C3 and CS 
convertase, as well as the membrane attack unit, can be constructed and ac-
tivated. The major differences of the two pathways reside in the mode and 
specificity of initial activation, and in the use or bypassing of components 
Cl, C2, and C4. 
Investigations utilizing reactions of Gram-negative bacteria or LPS 
with complement have involved bactericidal action, significant complement 
consumption profiles, reactivity in complement-deficient sera, and the gen-
eration of biologically active products (Wardlaw, 1964; Bladen et al., 1967; 
Gewurz et al., 1968a,c, 1969b; Mergenhagen et al., 1969; and Fine, 1972 and 
1974). 
The endotoxin from a variety of organisms (Veillonella alcalescens, 
Serratia marcescens, Salmonella typhosa, and Escherichia coli) has demon-
strated the ability to activate complement when incubated with guinea pig, 
human, and primitive vertebrate sera (Pillemer et al., 1955; Gilbert and 
Braude, 1962; Miller et al., 1966; Gewurz et al., 1968; and Day et al., 1970). 
Microgram amounts of LPS caused significant depletion of complement levels in 
all species that exhibited antibody-induced hemolytic activity (Day et al., 
1070). Complement activation was evident in these reactions by the presence 
of multiple lesions on the surface of LPS particles. 
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Complement fixation by LPS has been examined in view of the initia-
tion of biological reactions, and in comparison to classical complement fix-
ation. It was reported that factors exist (alternate pathway proteins) in 
normal guinea pig and human sera to initiate complement fixation upon incu-
bation with LPS in the absence of exogenous antibody (Bladen et al., 1967; 
Day et al,, 1970; Gewurz et al., 1968a and 1971). Endotoxin depleted the 
six terminal complement components (C3-C9) with minimal consumption of Cl, 
CZ, and C4 (Gewurz et al., 1968b). In addition, Gewurz et al., (1968b and 
1971) have reported that the LPS of V. alcalescens consumed significantly 
greater amounts of terminal components than either the zymosan activated al-
ternate pathway, or immune complex activated classic pathway. 
These reactions were further examined utilizing sera from man, pig, 
and cow with developmental agammaglobulinemia (Gewurz et al., 1969a and 
1970). Depletion of complement ensued in each of the vertebrate sera, ex-
cept human, when challenged with LPS, and the percent fixation was compara-
ble to irnmunoglobulin-normal control animals. However, the lower level of 
complement consumption in human agammaglobulinemic, Cl-deficient, and C2-
deficient sera implied the requirement of an efficient use of anti-LPS im-
munoglobulins with Cl, CZ, and C4 in the formation of an intermediate C3 con-
vertase (Gewurz et al., 197la,b; Synderman et al., 197lc). 
Further examination of LPS-vertebrate complement reactions demonstrated 
complement activation and efficient consumption of terminal components in 
the absence of C4b-C2a (Marcus et al., 1971; and Frank et al., 1970). This 
supported the concept of alternate pathway activation in the absence of im-
mune complexes. The minimal consumption of Cl, C2, and C4 in LPS-guinea 
pig serum incubations was determined to be the result of a natural anti-
body. In addition, chelation of human serum with EGTA (binds Ca++ more av-
idly than Mg++) inhibited classical complement activation, but allowed al-
ternate pathway activation when challenged with erythrocyte-labeled LPS 
(E-LPS) (Fine, 1972 and 1974; Forsgren et al., 1975). Thus, LPS activates 
the alternate pathway of complement fixation, and is capable of terminating 
in a membrane attack unit.independent of antibody mediation. 
Ample evidence exists to demonstrate the role of complement (C5b-6-7-
8""9J :tn bactericidal reactions initiated by immune complexes (Muller-Eber-
hard, 1966 and 1975; Rapp and Boros, 1966; and Nelson, 1965). LPS is also 
capable of acting as a substrate for this reaction, which consumes signifi-
cant amounts of the six terminal components (Boros, 1964; Radding et al., 
1966; Bladen et al., 1966; Gewurz et al., 1970 and 1971; and Mergenhagen et 
al., 1968). The incubation of guinea pig sera with LPS or Gram-negative 
bacteria regularly induces lesions on the particle surface, which are char-
acteristic of complement activation (Bladen et al., 1967; and Mergenhagen 
15 
et al., 1969). When guinea pig sera was treated with a number of complement 
inhibitors, the loss of.the ability to lyse sensitized red blood cells was 
associated with the absence of lesions on the LPS surface of V. alcalescens 
(Bladen et al., 1967; and Mergenhagen et al., 1968). Lesions on endotoxin 
are consequent to the activation of complement and the interaction of mul-
tiple complement components. In the formation of such lesions, given amounts 
of LPS consumed greater quantities of C3 to C9 than either immune complexes 
16 
or aggregated human gammaglobulin (Gewurz et al., 1969b). 
Activation of the clotting system by LPS-complement activation is an-
other factor in the pathological effects of LPS (Thomas, 1954; Mergenhagen 
et al., 1969). The injection of LPS into a suitable host causes a pro-
found thrombocytopenia, which is characterized by the deposition of agglu-
tinated platelets in the liver, spleen, and lung (McKay and Shapiro, 1958; 
Stetson, 1951). In vivo reactions of LPS cause platelet degranulation and 
release of factors (histamine and platelet factor three, P.F.3) through a 
heat-labile, cation-dependent, plasma system (Horowitz et al., 1962; Des 
Perez and Bryant, 1966). Complement was implicated as the mediator of the 
LPS-platelet reaction, and a Mg++ requirement implicated the alternate path-
way as the apparent in vitro mechanism (Spievogel, 1967; Nelson, 1965; Se-
quieria and Nelson, 1961; Gocke and Osler, 1965; Sandberg et al., 1971; 
Zucker and Grimm, 1974; and Pfueller and Luscher, 1974). 
Endotoxin activation of the clotting mechanism appeared to require C3, 
C3 proactivator (Pa), and possibly properdin as necessary factors (Zucher 
et al., 1974; and Kane et al., 1973). However, a fault in the clotting mech-
anism of C6-deficient rabbits implicated the membrane attack unit from ei-
ther pathway as the mediator of platelet degranulation (Zimmerman, 1971). 
The reaction appears to be a noncytolytic event (lack of CS and C9) in 
which C3, CS, C6, and C7 are required (Kane et al., 1973; and Graff et al., 
1976). Thus, the aggregation of platelets, degranulation, and activation 
of P.F. 3 by endotoxin-complement interaction may represent a possible mech-
anism of the pathological intravascular coagulation seen in Schwartzman-
type reactions and Gram-negative sepsis (Zimmerman, 1973; and Brown and 
Lachmann, 1973). 
Endotoxic lipopolysaccharides of Gram-negative bacteria are macro-
molecular complexes which are composed of two chemical moieties: a com-
plex heteropolysaccharide and a lipid portion, lipid A (Shands, 1971; 
and Gewurz et al., 1971). LPS is rich in antigenic determinants with 
which immunoglobulins frequently react (Neter, 1969). 
A number of morphological studies on LPS of various bacterial gen-
17 
era have shown superficial structural similarities in a trilaminar arrange-
ment, which could be connnon to all gram negative lipopolysaccharides 
(Shands, 1971; Rothfield et al., 1966; Bladen et al., 1967; De Petris, 
1967; and Knoz et al., 1967). This structure consists of linear repeat-
ing oligosaccharides ("O" antigen) linked to a core polysaccharide, which 
is covalently linked to the lipid A moiety (Luderitz et al., 1966b). Lipid 
A is a highly substituted, long chain fatty acid derivitive of a phos-
phorylated hexosamine-disaccharide backbone: 4-phosphoglucosaminyl-B-1, 
6-glucosamine-1-phosphate (Westphal, 1975). The core polysaccharide forms 
an ester bond to the hexosamine unit connnonly with KDO (2-keto-3-deoxyoc-
tanate). The polysaccharide contains five sugar constituents in most en-
dotoxins, and commonly consists of a heptose, glucose, galactose, and glu-
cosamine (besides KDO) (Westphal, 1975). Three hydroxyl groups on the 
disacchariqe backbone are esterified with !auric (c12 ), myristic (c14), 
and palmitic (c16 ) acids. An ester linkage to the KDO unit is formed at 
a fourth hydroxyl group (Luderitz, et al., 1973). 
It appears that the polysaccharide components of the LPS molecule 
do not play any specific role in endotoxicity (Galanos et al., 1971). 
However, the polysaccharides attached to lipid A may render it more sol-
uble by influencing the conformation, which indirectly effects endotoxic 
reactions (Galanos et al., 1972; Morrison, 1976; Loos et al., 1974; and 
Lachman and Nicol, 1974. Purified suspensions of "O" antigens and core 
polysaccharide have been found to be ineffective in alternate complement 
pathway activation (Mergenhagen et al., 1961). 
Complement activation is not a property connnon to all lipopolysac-
charides, though, the isolated lipid A from both active and non-active 
endotoxin is strongly toxic and anticomplementary when solublized by a 
suitable carrier (Galanos, 1971). The reaction with complement does not 
result in any chemical or compositional changes, but does result in the 
loss of solubility in water and loss of biological activity. 
The participation of complement in infiammation and tissue destruc-
tion has been partially attributed to the production of anaphylactic and 
chemotactic factors through both pathways (Mergenhagen, 1970,1972a; Muller-
Eberhard, 1972a; Budzko et al., 1971; and Hugli, 1975b,a). The developing 
sequellae of reactions, following the injection of immune complex-adsorbed 
serum in guinea pigs, was first proposed to be the effect of a toxic fac-
tor (anaphylatoxin) generated from the serum (Freidberger, 1910). General-
ly, anaphylatoxin is a pharmacologically active substance that causes con-
traction of the guinea pig ileum, is blocked by anti-histamines, increases 
vascular permeability, and degranulates mast cells (Mergenhagen et al., 
1969). 
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The function of complement in anaphylatoxin generation was first 
recognized by Osler et al., (19S9a,b). Hemolytic complement fixation 
was necessary for rat skin-bluing activity when immune complexes, agar, 
inulin, dextran, liquoid, and zymosan were incubated with rat serum. 
Through the inhibition of complement activity, the immune aggregates were 
unable to produce anaphylatoxins upon incubation. Cl esterase activation 
of guinea pig sera also generated factor (s) that fulfilled the estab-
lished critereon for anaphylatoxin (Rattnoff and Lepow, 1963; and Dias 
Da Silva and Lepow, 1966a). The reactions were dependent on the parti-
cipation of complement factors beyond Cl, C2, and C4. 
In separate reactions, purified complement components were incubated 
with a number of factors (LPS, CVF, immune aggregates, and polysaccharides) 
which stimulated the release of anaphylatoxin. This factor could be pro-
duced by tryptic cleavage of CS, but was also generated in solutions con-
taining only Cl, C2, C4, and C3 (Jensen, 1966, 1967; Dias Da Silva and 
Lepow, 1966a, 1967; and Cochrane and Muller-Eberhard, 1968). The latter 
stimulated the in vitro degranulation of mast cells, and was unaffected 
by the addition of CS. Further examination of these reactions revealed 
that the fluid phase anaphylatoxin was generated from a reaction of Cl, 
C2, C4, and C3. This factor was cleaved from C3 (C3a), and had an approx-
imate molecular weight of 6800 (Shin et al., 1969a; Dias Da Silva et al., 
1967; and Cochrane and Muller-Eberhard, 1968). Utilizing sheep red blood 
cell-bound complement intermediates (C2a-C4b-C3), anaphylatoxin was gen-
erated from CS (CSa), and caused contraction of the guinea pig ileum. The 
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cleavage of CS appeared to be dependent upon the formation of a cell-bound 
CS convertase, and generated a factor (lS,000 daltons) with both anaphyl-
actic and chemotactic abilities. Thus, C3a and CSa serve as anaphyla-
toxins when activated by known initiators of the classical complement se-
quence (Mergenhagen et al., 1969). 
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The experimental evidence that endotoxins induce anaphylatoxins from 
whole serum strongly indicates complement factors identical to those men-
tioned previously, and have become apparent with the current molecular model 
of alternate pathway activation. The incubation of LPS (y_. alcalescens and 
E. coli) in rat plasma and guinea pig sera produced the capacity to con-
tract the guinea pig ileum in a manner analogous to anaphylatoxin (Greis-
man, 1960; and Lichtenstein et al., 1969). A positive correlation was 
made between LPS-activation of terminal complement components and the ap-
pearance of anaphylactic activity. Furthermore, these reactions were in-
hibited by anti-histamines and complement inactivation. 
Several investigators have determined that LPS-complement activation 
cleaves small molecular weight fragments from guinea pig C3 and CS (C3a 
and CSa), which retain anaphylactic and chemotactic activity (Jensen et al., 
1969; and Synderman et al., 1969). Incubation of LPS, lipid A, or zymosan 
in human, guinea pig, or hamster sera generates C3a and CSa via the alter-
nate pathway (Brade and Vogt, 1972; Hook, 1970; and Dierich et al., 1973). 
The anaphylatoxins released in these reactions caused the degranulation 
of mast cells and human basophilic leukocytes, releasing histamine and hep-
arin (Hook, 1970; Muller-Eberhard, 197S; Gewurz et al., 1971; Johnson et al., 
1975; and Hook et al., 1975). Isolated C5a from LPS-stimulated serum has 
been shown to cause typical anaphylactic responses. The subcutaneous in-
jection of this factor in rabbits and rats produced an intense inflamma-
tory reaction that resembled the Arthus phenomenon in lesion formation 
and time course (Synderrnan et al., 1971, 1969; and Jensen et al., 1969). 
In addition to C3a and C5a, LPS-complement reactions liberate or ac-
tivate a histamine-heparin releasing factor with vasoactive properties. 
The expression of vasoactivity by this factor, a 60,000 molecular weight 
~-2 globulin, is dependent on complement initiation, but is inconsistent 
with published data on complement anaphylatoxins (Hook et al., 1972). 
Both C3a and C5a have been recognized in human serum, but were con-
sidered insignificant due to negligable biological activity in experimen-
tal systems (Muller-Eberhard and Vallota, 1971; and Bokisch and Muller-
Eberhard, 1970). The isolation and characterization of an anaphylatoxin 
inactivator (AI) revealed a control mechanism for human complement ana-
phylatoxins. The factor occurs in trace amounts as a carboxypeptidase 
that functions by the removal of the C-terrninal amino acid residue on both 
C3a and C5a (Vallota and Muller-Eberhard, 1973; and Bokisch et al., 1975). 
The removal of AI allowed the generation of anaphylatoxins through both 
complement pathways by LPS, inulin, and immune complexes. It was deter-
mined that human anaphylatoxins are not significantly different from those 
of other mammalian species, and that C5a (16,500) is one thousand fold 
more biologically active than C3a (9,000), on a molar basis. 
Polymorphonuclear leukocyte (PMN) accumulation follows the intra-
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dermal injection of microgram amounts of endotoxin, and is one character-
istic pathological change induced by LPS (Stetson, 1951; and Thomas, 1954). 
Similar i.p. injections of sub-microgram amounts caused a dramatic increase 
in PMN accumulation in peritoneal exudates (Fruhman, 1959). The mechanism 
mediating these responses was examined, in vitro, following the develop-
ment of a suitable assay by Boyden (1962). The assay measured leukocyte 
migration through a Millipore filter within an acrylic diffusion chamber. 
Innnune complexes incubated in guinea pig serum caused the chemotaxis 
of PMN leukocytes through the activation of a heat-labile serum enzyme 
system (Boyden, 1962). Similarly, aggregated human gamma globulins alone 
could not generate chemotaxis, but produced this activity when incubated 
in rabbit serum (Keller and Sorkin, 1965). Further studies determined 
that a chemotactic component was derived from the complement system, and 
is composed of a trimolecular complex of C5b-6-7, with a molecular weight 
of 300,000 (Ward et al., 1965, 1966). A second factor derived from C3 
(C3a), with a molecular weight of 8,000, also exhibited chemotactic attrac-
tion to rabbit PMN leukocytes (Ward, 1967). 
The incubation of microgram amounts of LPS from V. alcalescens and S. 
marcescens in human, guinea pig, and rabbit serum induced chemotactic ac-
tivity for PMNs (Synderman et al., 1968). Various inhibitors of comple-
ment also halted chemotaxis in LPS-stimulated serum. The active component 
was identified as a peptide with a molecular weight of 15,000 which was 
antigenically identical to the complement anaphylatoxin, C5a (Synderman 
et al., 1968, 1969; and Shin et al., 1968). C5-6-7 and C3a chemotactic 
factors were found to possess weak biological activity in the chemotactic 
attraction of PMN leukocytes (Shin et al., 1969b). 
The intradermal injection of CSa in rabbits caused increased vascu-
lar permeability and neutrophil accumulation (Jensen et al., 1969; and 
Shin et al., 1969b). This led to the hypothesis that complement activa-
tion, as a biological effector of inflanunation through anaphylactic and 
chemotacic activities, mediates certain pathologic effects of bacterial 
LPS (Ward and Newman, 1969). 
Synderman et al., (1971) investigated the role of C5a in the early 
accumulation of PMNs in inflammatory exudates. A 0.5% glycogen solution 
was injected i.p. in guinea pigs, and exudates were extracted at 30 min-
utes, 1, 2, 3, 4, 5, 6, 27, and 48 hours. PMN levels increased to a max-
imum from 2 to 6 hours (260 x 106 /ml), and then decreased to 48 hours. 
The chemotactic factor was present after 30 minutes, and increased to a 
maximum at 2 hours. CS-deficient mice, highly susceptible to microbial 
infection, were unable to duplicate this experiment. 
Guinea pig, mouse, and human mononuclear leukocytes also respond chem-
otactically to C5a, in vitro. This factor may be responsible for mono-
cyte accumulation in wound healing, and could mediate tissue damage in 
sensitive tissues (Synderman et al., 197lb, 1972a, and 1975; and Lett-
Brown, 1976). 
Human basophilic leukocytes have been found to respond chemotactically 
to a number of factors, including CSa. In mixed populations of leukocytes, 
a 5-10% basophil population responded to zymosan, LPS, and trypsin-gener-
ated C5a, together with neutrophils and monocytes (Kay and Austen, 1970; 
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and Ward et al., 1975). 
Eosinophils have also been demonstrated to respond chemotactically 
to a trypsin-derived C5a in mixed population of leukocytes. When the 
eosinophil population exceeded 10% in the Boyden test chamber, C5a selec-
tively attracted these cells with minimal migration of neutrophils (Kay 
et al., 1973). 
Thus, C5a generated from both complement pathways mediates the direc-
ted migration of blood leukocytes, especially PMNs and monocytes. This 
has been proposed as the second major biological activity of complement 
as a mediator of the inflammatory response (Muller-Eberhard, 1972a; and 
Mergenhagen, 1972). 
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MATERIALS AND METHODS 
Organism and growth conditions 
Veillonella alcalescens Cl, a Gram-negative anaerobe (diplococcus) 
isolate from sheep rumen, was supplied by Dr. E.A. Delwiche of the College 
of Food Sciences, Cornell University in Ithaca, New York. Initial cultures 
(1.8 liters) were grown in a pre-reduced lactate medium in 2000 ml flasks 
for seventy-two hours at 37°C. This liquid medium was overlayed with ster-
ile paraffin oil (degased) to insure reduced conditions under incubation. 
This medium was prepared according to Virginia Polytechnic Institute spe-
cification (VPI Anaerobe Lab Manual, 1975), and was used within one day 
of preparation. The medium was a peptone-yeast-lactate (PY-L) with the 
following formula: 10 gm peptone (Difeo), 10 gm yeast extract (BBL), 4 ml 
resazurin solution (0.25 mg per ml H20), 40 ml salts solution (0.2 gm 
CaC12 , 0.2 gm MgS04 7H20, 1.0 gm K2HP04 , 1.0 gm KH2
Po4 , 10 gm NaHC03
, and 
2.0 gm NaCl per 1000 ml distilled H20), and 9 ml 85% lactic acid added to 
1000 ml distilled water. The pH was adjusted to 7.0 with 8N NaOH and boiled 
until the resazurin indicator became colorless. Then 0.5 gm cysteine hydro-
chloride (Eastman) was added as a reducing agent, the pH readjusted to 7.0, 
and the medium autoclaved. Cells were harvested, washed in cold saline 
(0.15M NaCl), resuspended in 40 ml sterile skim milk, and lyophilized. 
Viable cultures were maintained on pre-reduced brain-heart infusion agar 
plates containing 3.7% B.H.I., 0.5% yeast extract, 0.4% resazurin solution, 
and 0.05% cysteine hydrochloride. The plates were incubated in vented Gas 
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Pack anaerobic jars (BBL) at 37°C, and were transferred once every three 
days. Anaerobic conditions in the jar were established by flushing twice 
with anaerobic grade co2, and filling the jar with gas composed of 10.34% 
co2 , 10.0% H2 , and the balance N2 • Disposable anaerobic indicators (BBL) 
with methylene blue and the resazurin in the media were used to monitor 
anaerobic conditions in the jar. 
Extraction of bacterial endotoxin 
For the routine extraction of endotoxin from Veillonella alcalescens, 
three flasks, each containing 250 ml of PY-L, were innoculated from single 
colonies of V. alcalescens and incubated at 37°C for forty-eight hours. 
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These cultures were used to innoculate six (1 starter culture per 2 liters) 
liters of PY-L, which were subsequently incubated for seventy-two hours at 
37°C. The cells were grown to 109 per ml, harvested with a Beckman J-21 
centrifuge at 15,380 x g for thirty minutes, washed three times in cold saline 
(0.15M NaCl), and resuspended in 40 ml of saline. Cell walls were disrupted 
by sonication (Blackstone) at two minute intervals, followed by two minutes 
cooling at 4°C, for a total of twenty-two minutes of actual sonication. This 
procedure was performed with extreme care to generate a minimum amount of 
heat to the cell walls by using ice baths. Cell lysis was measured by phase 
contrast microscopy and viable counts (pour-plate technique), Cell wall de-
bris was harvested by centrifugation (Beckman J-21) at 27,300 x g for two 
hours. The cell wall pellet was resuspended in sterile distilled water and 
centrifuged. This washing procedure was repeated six times, and the pellet 
of cell wall material was finally resuspended in 50 ml of distilled water. 
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Endotoxin was extracted by the phenol-water method of Westphal (1952,1971), 
as diagramed in figure 3. The yield of purified LPS from whole bacterial 
cells was approximately 1.72% (9.8 mg of endotoxin) of the dry weight. 
Experimental animals 
Young adult female guinea pigs (Scientific Small Animal), from 500 to 
700 grams, were housed in a thermostatically controlled and humidified room, 
with a diurnal variation of light, at Loyola University Dental School Ani-
mal Care Facility. They were contained in large metal cages with mesh bot-
toms, and were fed Purina guinea pig chow and water (supplemented with as-
corbic acid) ad libitum. Adult New Zealand rabbits, from 2 to 3 kilograms, 
were also housed under similar conditions. They were watered and fed Pur-
ina rabbit chow and lettuce ad libitum. Only clinically healthy rabbits 
were considered for use in experimental studies. 
Source of complement 
Complement was collected from healthy, female guinea pigs by cardiac 
puncture. An intravenous infusion set (19 gauge, 7/8 inch needle) was con-
nected to a #5 1/2 rubber stopper with a glass-tube lead for attachment to 
a small vacuum pump. The complete sterile apparatus was aseptically at-
tached to a 50 ml conical centrifuge tube (I.E.C.), and blood was collected 
from the guinea pigs under vacuum (2 psi). The blood was allowed to clot 
at room temperature for fifteen minutes, the tubes rimmed with sterile ap-
plicator sticks, and centrifuged at 160 x g for thirty minutes in an In-
ternational Clinical Centrifuge (I.E.C.). The separated serum was col-
FIGURE 3 
Phenol-water extraction of endotoxin 
50 ml of an 89% phenol solution, heated to 56°C, was added 
to the 50 ml cell wall suspension, and heated for thirty 
minutes at 56°C with continuous stirring. 
The suspension was cooled to 4°C and centrifuged at 27,300 x g 
for one hour, resulting in a distinct phase separation of 
phenol and water. 
Aqueous phase I 
Aqueous phase II 
Phenolrh••• 
50 ml distilled 
water added to 
phenol phase, heated 
for 30 min. at 56°C 
with stirring, and 
cooled to 4°C. 
Centriflgation was 
repeated at 27,300 
x g for 1 hour. /i 
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Phenol phase 
was discarded. 
The aqueous phases (upper phase) were dialyzed against 
distilled water to remove phenol, as indicated by the 
lack of detectable odor. 
i 
Endotoxin was precipitated from the water by the addition 
of granular sodium acetate (Sigma) to a final concentration 
of 0.15M and absolute ethanol dropwise to a final volume 
concentration of 68% while stirring at 4°C. 
i 
The solution was kept at 4°C over night to allow precipitation. 
i 
The precipitate was separated by centrifugation at 1000 x g 
for thirty min. 
l 
The pellet from centrifugation was resuspended in 25 ml 
of distilled water and dialyzed against distilled water 
to remove traces of ethanol. 
i 
Lyophilization yielded the purified endotoxin. 
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lected by sterile Pasteur pipets, placed in sterile tubes, and immediately 
frozen at -58°C (Revco). When approximately 30 ml of serum had been col-
lected, it was pooled, divided into 1 ml aliquots, and frozen at -58°C. 
Whole guinea pig serum was used as the complement source in all assays 
performed. 
Source of antiserum 
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Anti-y_. alcalescens serum was prepared by injecting six female guinea 
pigs with heat-killed whole cells of V. alcalescens Cl, The saline cell sus-
pensions (0,15M NaCl) were emulsified in complete Freund's adjuvant (Difeo), 
and injected at a rate of three injections per week for five weeks. The in-
jections consisted of increasing doses from 0.1 mg to 1,0 mg of dry whole 
cells, and were administered by intramuscular and subcutaneous routes, al-
ternately. At the end of thirty-five days the animals were bled (36th day). 
Six days later they were boosted with 1.0 ml of a 1 mg per ml suspension of 
y_. alcalescens subcutaneously. The following day they were again boosted in-
traperitoneally with 1.0 ml of the same suspension. Six days later they were 
again bled. Following this schedule, the guinea pigs were boosted with the 
cell suspension and bled on alternate weeks until approximately 40 ml of an-
tisera had been collected (Hagen, 1972). Serum was separated and collected 
as already described, and was frozen in large tubes at -58°C. All injections 
were performed with disposable 3cc syringes with 22 gauge, 1 1/4 inch needles. 
Pre-immunization bleedings were performed with a guinea pig bleeding ap-
paratus, which used a 15 psi vacuum to collect blood from the tarsus vein. An-
tisera was collected by cardiac puncture. All samples with a passive hemag-
glutination titer of 5120 or above, were pooled, heat-inactivated at 56°C for 
31 
thirty minutes, decanted into vials, and frozen at -58°C until used (Weir, 
1967). 
Rabbit polymorphonuclear leukocytes 
Polymorphonuclear leukocytes were collected from peritoneal exudates by 
a modified method of Sbarra and Karnovsky (1959). A 110 ml solution of 8% 
casein (Matheson, Coleman, and Bell) in saline (0.15M NaCl), supplemented 
with 50 µg neomycin per ml, was injected intraperitoneally with a 50cc syringe 
and 18 gauge needle. Approximately eighteen hours later, the cells were col-
lected by injecting 150 ml of heparinized saline (10 units per ml) into the 
peritoneal cavity. The exudate was immediately aspirated from the lowest 
point in the cavity. An 18 gauge, 1 1/2 inch needle mounted in heparinized 
rubber tubing was connected to a glass tube lead into a #5 1/2 rubber stopper 
as previously described. This vacuum device was aseptically inserted into an 
I.E.C. conical centrifuge tube, and was used to aspirate fluid from the rab-
bit peritoneum. The leukocyte suspension was harvested by centrifugation for 
ten minutes at 160 x g, and resuspended in Gey's balanced salt solution (Difeo) 
containing 2% BSA (Difeo), 50 µg streptomycin per ml, 50 units penicillin per 
ml, and 10 units heparin per ml (Synderman et al., 1968). Leukocytes were 
counted by standard clinical procedures utilizing a Neubauer hemacytometer 
(American Optical Co.), and adjusted to 3 x 106 cells per ml with Gey's medium. 
Differential counts of two hundred Wright stained cells determined the number 
of PMN leukocytes in suspension (Brown, 1975). The counts ranged from 86 to 
95.5% PMNs, with minimal numbers of monocytes, lymphocytes, and eosinophils. 
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Chelation of complement and antisera 
Pooled guinea pig complement and anti-V. alcalescens sera were chelated 
with ethyleneglycol-bis(S-amino-ethyl ether) N,N'-tetra acetic acid (EGTA, 
Sigma) according to the procedure of Fine (1972, 1974; and Forsgren et al., 
1975). Chelation with lOmM MgEGTA selectively removed ca++- and classical 
complement activity, leaving the alternate pathway intact. Sterile O.lM 
MgEGTA was used to chelate reaction mixtures by adding 0.015 ml of this solu-
tion to each 0.15 ml of antiserum and complement prior to incubation. 
Chelator stock solutions of 0.1 M MgEGTA were prepared by disolving EGTA 
in normal saline (0.15M NaCl). The mixture was heated to 60°C, and 5N NaOH 
was added dropwise until EGTA went into solution. This mixture was adjusted 
to a final pH of 7.45 with IN HCl. Granular MgCl was then added to the solu-
2 
tion, which was brought to a final concentration of O.lM (MgCl & EGTA) with 
2 
saline, and autoclaved. 
Chemotaxis reaction mixtures 
In the preliminary studies, a measured quantity of lyophilized cell wall 
sonicate or LPS was diluted in 0.15M veronal buffered saline (VBS), pH 7.3, 
to 0.15 ml and incubated with 0.15 ml guinea pig complement for thirty minutes 
at 37°C. The mixture was then removed and heat-inactivated at 56°C for thirty 
minutes to prevent any further complement activity. The mixture was then di-
luted to 1.5 ml in Gey's medium (final serum concentration 10%), and utilized 
in a chemotaxis assay (Synderman et al., 1968, 1969; and Keller et al., 1976). 
In the normal immune serum reactions, 50 µg of LPS in 0.15 ml VBS was 
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incubated with 0.15 ml guinea pig complement and 0.15 ml anti-V. alcalescens 
sera (diluted to 0.48 ml with VBS) for thirty minutes at 37°C. This was fol-
lowed by heat-inactivation at 56°C for thirty minutes, dilution to 1.5 ml in 
Gey's medium, and measurement of chemotactic activity. In reactions of che-
lated serum, 50 µg LPS diluted in 0.15 ml VBS was incubated with 0.165 ml of 
chelated guinea pig complement and 0.165 ml of chelated anti-V. alcalescens 
sera for thirty minutes at 37°C. These mixtures were inactivated and measured 
for chemotactic activity. All reaction mixtures in this series of experi-
ments had a final serum concentration of 20% (Keller et al., 1976). Controls 
consisted of normal and chelated serum samples mixed with 0.15 ml VBS in place 
of endotoxin. They were incubated, heat-inactivated, and assayed for chemo-
tactic activity. 
Quantitation of chemotaxis 
Measurement of complement activation was quantitated using a modified 
Boyden diffusion chamber (Neuroprobe, Inc., Bethesda). Permeable 8 micron and 
impermeable 0.45 micron Millipore filters were used to separate the two cham-
bers of this chemotaxis assay system. Prior to assembly of the diffusion 
chamber (figure 4), the filters were thoroughly soaked in Gey's medium 
to prevent the entrampment of air between them. They were immediately placed 
in the filter retainer groove, and the filter retainer was carefully screwed 
into place. Approximately 1 ml of chemotactic mixture was placed, with a 
Pasteur pipet, in the lower compartment of the chamber, which was tilted to 
remove any air bubbles collecting at the lower (0.45 micron) filter surface. 
The prevention of leakage into the upper compartment assured proper positioning 
Chemotactic solution PMN leukocyte solution 
Teflon 
plug 
\ / [] 
side view 
Che~otactic---\~----() 
mixture , \ 
Leukocyte 
suspension 
top view 
FIGURE 4 
13 mm diameter 
~roove for fil-
ters. 8 micron 
filter placed 
above .45 mic-
ron filter. 
Modified Boyden Diffusion Chamber 
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of filters. Immediately following, 0.56 ml of the leukocyte suspension was 
placed in the upper chamber compartment (teflon filter retainer) simultaneous 
with the placement of the remaining chemotactic mixture in the lower compart-
ment. The solutions in both compartments allowed a very slight overflow, 
which resolved fluid levels and reduced va~iability in leukocyte migration due 
to hydostatic pressure. The charged Boyden chambers were incubated for sixty 
minutes at 37°C with precautionary measures taken to prevent vibrations and 
movement (Keller et al., 1972, 1976). 
Assessment of chemotaxis was measured by the direct quantitation of PMNs 
which migrated across the Millipore filters. The filters were removed to-
gether from the chamber, gently rinsed in Gey's medium, placed on a standard 
microscope slide, and stained by the following procedure: 5 minutes fixation 
in 85% ethanol, rinse in distilled H20; separate filters with the lower sur-
face of the 9 micron filter facing up, stain with hematoxylin 5 minutes, rinse 
in distilled H20; dehydration with 70% ethanol (2 minutes), 95% ethanol (2 
minutes), and absolute ethanol (3 minutes). The filters were then cleared in 
xylene and mounted with permount (Fischer). The number of PMNs that complete-
ly migrated through the filters were counted in ten random fields on the ex-
treme lower surface of the 8 micron filter and on the upper surface of the 
0.45 micron filter. The cells were counted under high power (43x) with the 
aid of a microgrid. The mean and probable error of measurement (P.E.M.) was 
calculated for each test and control. A between-within analysis of variance 
was computed between each test and control in both the chelated and normal 
serum samples. In addition, the same statistical analysis was computed be-
tween the normal reaction mixtures and the chelated mixtures to determine the 
difference, if any, in chemotaxis generated from the alternate complement 
pathway, with and without classic pathway activation. 
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The Boyden chambers were completely disassembled and scrupulously clean-
ed following each chemotaxis assay. They were rinsed in tap, de-ionized, 
and distilled water, and allowed to dry in a relatively dust free environ-
ment under an ultra-violet light hood. Prior to each days use, they were sub-
mitted to ultra-violet radiation for three hours. 
Measurement of residual hemolytic complement activity 
Residual levels of hemolytic complement in chelated and normal serum were 
measured and reported in C1H50 units according to the method of Mayer (Kabat 
and Mayer, 1961). These experiments were performed by allowing the desired 
amount of antigen (LPS) and antibody react with a large quantity of comple-
ment. At the end of the fixation period, accurately measured aliquots of the 
reaction mixtures were measured for hemolytic complement levels by a photo-
metric procedure. Sheep red blood cells were sensitized with rabbit anti-
sheep hemolysin (Difeo). This was accomplished by harvesting fresh red blood 
cells from sheep blood, which were suspended in VBS at 5 x 10 8 per ml with the 
use of a hemacytometer. These cells were subsequently concentrated to 1 x 109 
per ml. The cells were optimally sensitized by the addition of 12.5 ml of a 
1:400 dilution of anti-sheep hemolysin to 12.5 ml of red cells, which brought 
the final concentration to 5 x 10 8 per ml. This mixture was gently agitated 
for 5 minutes, and then incubated for sixty minutes at 37°C. 
A 2.5 ml dilution of 50 µg LPS in VBS was mixed with 5.0 ml of a 1:10 
dilution of complement and 2.5 ml of a 1:10 dilution of anti-V. alcalescens 
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sera. Two identical 10 ml reaction mixtures were prepared with 50 µg of LPS 
in similar 1:10 dilutions of chelated complement and chelated antisera. Con-
trols consisted of VBS substituted for LPS in all three reaction mixtures. 
All components were accurately measured and combined at 4°C (to retard ac-
tivity), and were incubated for ninety minutes at 37°C in a water bath. At 
the end of the incubation period the tubes were removed, placed in an ice 
bath, and prepared for measurement of hemolytic activity. Both 4.0 and 5.0 
ml quantities of a 1:10 dilution of each reaction mixture and control were 
placed in sterile tubes, diluted to 6.5 ml with VBS, mixed with 1.0 ml of 
sensitized sheep red blood cells, and incubated for ninety minutes at 37°C. 
Dilution blanks with 1.0 ml red blood cells and 6.5 ml VBS were also incu-
bated for ninety minutes. One set of chelated reaction mixtures and con-
trols were recalcified with sterile CaC12 solution at a final concentration 
of lOmM, prior to mixture with the amboceptor. 
At the conclusion of the incubation period, all the tubes were removed 
and centrifuged at 160 x g. The supernatant of each tube was removed, and 
the optical density (O.D.) of oxyhemoglobin was read at a wavelength of 
550 mµ in a Coleman Jr. spectrophotometer. The supernatant from the red 
cell VBS blanks was used as the blank in the readings of O.D. A reading was 
made of a 1:10 dilution of complement and antisera against a saline blank to 
determine a correction factor for serum absorbance. The per cent lysis of 
5 x 10 8 cells/ml was determined by dividing the corrected O.D. of reaction 
mixtures by the O.D. of 100% lysis. The latter was produced by freezing and 
thawing 1.0 ml of sensitized cells in 6.5 ml of VBS three times. The per 
cent lysis was transformed into C1 H50 units from published values (Kabat and 
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Mayer, 1961) based on the von Krogh equation, x=K(y/1-y)l/n(mathematical ex-
pression of the sigmoidal response curve of hemolytic complement activity). 
These residual complement levels represent a control for the chelation of 
serum by EGTA in the chemotaxis assay. 
Results 
Activation of complement chemotactic factors in the absence of immune sera 
Chemotaxis of leukocytes in a Boyden diffusion chamber is the most 
sensitive assay of biological activity generated from complement activa-
tion (Synderman et al., 1968, 1969, 1971, 1975). It quantitatively meas-
ures reaction products and activity, where immune hemolysis and the C3 to 
C9 assay qualitatively measure the small percentage of complement capable 
of effecting the lysis of sensitized erythrocytes. 
To insure accurate measurement of chemotaxis, only those cells which 
completely migrated through the 8 micron filter were counted. The cells 
on the lower surface of the filter were observed to have distinct segment-
ed and lobulated nuclei, with the entire cell outline visible (figure 5). 
Cells in lower planes (focusing down from the lower surface) were under-
going diapedesis within the pore of the filter, and only varied shapes of 
the nucleus could be discerned. In addition, cells that completely mi-
grated through the filter and became detached, were collected on the 0.45 
micron filter. These varied from 5 to 30% of the total leukocytes counts 
in text mixtures, but accounted for only 0-5% in controls. All readings 
were reported as the mean of ten random high power fields ± the probable 
error of measurement (P.E.M.). The latter represents possible error in 
the readings due to judgement of the operators decision of whether a cell 
was within the plane of measurement or slightly below (within a pore). 
These are random errors associated with measurement, and are systematic. 
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rigure 5. PMN leukocytes on the lower surface of 
an 8 micron pore Millipore filter following incu-
bation in the Boyden chamber (43 x). 
40 
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Thus, if further measurements of 10 random fields were made, 50% of the 
readings should fall within the stated measurement± P.E.M. (Parratt, 1961). 
Varying quantities of y_. alcalescens Cl cell wall material ranging 
from 5 µg to 5 mg were incubated with guinea pig complement in chemotaxis 
assays. Although these were somewhat arbitrary units, their usage was 
loosely based on previous findings of !· coli activation of complement and 
pilot studies using !· coli LPS and Veillonella cell walls at concentrations 
between 0.5 µg and 500 µg (Fine, 1974). Activation of complement by cell 
wall material was evident in the increases of directed migration of PMNs 
(figure 6). The number of migrating cells almost doubled from 5 µg to 500 
µg, compared to minimal increases of 90.3 ± 4.5 to 103.4 ± 7.5, for cell 
concentrations between 500 µg and 5 mg. This is consistent with published 
data on complement activation in which LPS-generated chemotaxis reaches a 
plateau with increasing amounts of activator (Synderman et al., 1968). Con-
trols for these experiments were consistent with readings between 28.9 ± 
1.6 and 35.l ± 1.5. These numbers express the random migration of leuko-
cytes occuring throughout the incubation period. In statistical analysis, 
all test mixtures differed from positive controls with P < .01. Thus V. 
alcalescens Cl, the rumen strain, can generate complement chemotaxis simi-
lar to the oral strains. Strain Cl has a typical cell wall structure and 
chemical composition for Veillonella species (Winter & Delwiche, 1975), and 
also possesses biologically active lipopolysaccharide in that structure. 
The endotoxin extracted from Veillonella appeared to compose a very 
small quantity of the whole cell dry weight (1.7%). This does not neces-
sarily reflect weak endotoxic activity in V. alcalescens (Bladen et al., 
N 
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Figure 6 
Graphic expression of ~ a lcalescens Cl cell wall and endotoxin 
chemotactic activity in serum reactions. 
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1965; and Mergenhagen et al., 1961). The purified material was readily sol-
ubilized in distilled water, and adhered tenaceously to sheep red blood 
cells (for hemagglutination) at concentration of 50 µg per ml. An insolu-
ble preparation of LPS would have indicated complexing with divalent ca-
tions (Ca-I+ and Mg-I+) and an inability to generate significant biological 
activity (Shands, 1971). 
The purified endotoxin effected complement-mediated chemotaxis in con-
centrations from 0.05 µg to 50 µg. Both 0.05 µg and 0.5 µg produced simi-
lar migrations of PMNs (62.9 ± 3.9 and 60.3 ± 5.1), as did 5.0 µg and 50 µg 
(88.8 ± 5.6 and 102.5 ± 5.1). Although there was not as dramatic a differ-
ence within this series of experiments as with those from cell wall studies, 
they demonstrated a consistent ability to generate complement-mediated che-
motaxis in a Boyden system, with results comparable to or greater than those 
observed for cell wall material at hundred-fold higher concentrations. The 
controls varied slightly, from 16.9 ± 2.1 to 41.2 ± 1.4, but were all sig-
nificantly less than the test reading with P < .01. 
Based on this quantitation of complement chemotaxis for varying amounts 
of endotoxin, 50 µg was chosen as the quantity to activate immune and che-
lated test mixtures. This corroborates previous findings on the ability 
of the LPS of oral Veillonella strains, Serratia marcesens, and Salmonella 
species to generate maximum chemotaxis from a fixed quantity of guinea pig 
complement (Synderman et al., 1968, 1969; Mergenhagen et al., 1969; and 
Gewurz et al., 1971). 
LPS-chemotaxis in immune and chelated immune sera 
Eight in vitro immune reaction systems containing 50 µg LPS, anti-V. 
alcalescens sera, and complement, were tested and compared to eight iden-
tical reactions mixtures with MgEGTA chelated anti-sera and complement 
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for stimulation of chemotaxis (table 2). The normal serum reaction varied 
from 85.2 ± 4.5 to 227.4 ± 16.2 but not significantly enough to effect its 
relation to data on the chelated reactions (variance within the sample). 
The chelated reactions mixtures also had a varied sampling, from 60.1 ± 
12.2 to 204.7 ± 18.6. There was very little variation in the normal con-
trols (from 22.2 ± 2.5 to 38.8 ± 3.1), which were significantly less than 
the chemotaxis in the reaction mixtures (P .S. .001). Variation in the che-
lated controls was greater than that in samples previously examined (11.7 
± 1.4 to 81.3 ± 8.8). The controls were also significantly less (P < .001 
for 1, 2, 3, 4, 5, 8, and P < .05 for 7 and 6) than reaction mixtures. Che-
lation was performed with MgEGTA because of its ability to remove ca++, 
causing the disassociation of the Cl complexes, and the negation of classic 
complement activity with alternate pathway intact (Fine, 1972, 1974; and 
Forsgren et al., 1975). 
The chelated immune system generated chemotaxis in eight separate tests 
(mean= 94.6 ± 7.1) to levels which were not significantly different from 
the experiments with normal complement and anti-sera (108.7 ± 8.9). The 
latter is in a system in which a significant titer of immunoglobulin was 
reacting with an antigen and forming complexes capable of initiating clas-
sic complement fixation, while the alternate complement pathway was being 
effected. Thus, the alternate pathway in chelated serum can, in fact, gen-
erate biologically active products (C3a, C5a, C5b-6-7) for chemotaxis as 
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Table 2 
Quantitation of Chemotaxis in Normal & Chelated Serum 
Mean PMNs/10 fields±P.E.M. 
Test 
50µg LPS 50µg LPS Normal Chelated 
normal chelated control control 
1 143.9±8.3 119.2±4.1 29.4±3.4 11. 7±1.4 
2 90.0±6.4 121. 3±6. 6 23.7±1.7 12.7±2.3 
3 85.2±4.5 204.7±18.6 23.3±2 81. 3±8. 8 
4 139.3±8.8 184.2±5.2 37.8±3.l 27.0±2.6 
5 227.4±16.2 108.6±13 34.3±4.4 22.1±3.9 
6 132.3±13.2 59.3±3.3 30.7±2.l 35.1±3.7 
7 147. 3±21.1 79.6±7.6 22.2±2.5 43.7±4.5 
8 121. 2±10.5 69.1±12.2 37.3±2.4 21.1±1.4 
Quantitation of leukocytes in normal serum assayed 50 µg LPS as an 
activator of 0.15 ml anti-V. alcalescens and 0.15 ml complement. The 
chelator measurements were-assays of 50 µg LPS with chelated antisera 
and chelated complement. Controls substituted 0.15 ml VBS for the LPS. 
quickly and efficiently as the classic and alternate systems together (in 
fixed amounts of LPS, antibody, and complement). 
Measurement of residual hemolytic activity 
Hemolytic titers of complement were measured by an assay to determine 
the effect of chelation with MgEGTA on classic complement fixation. These 
experiments measured the number of C'H50 units present in a dilution of 
reaction mixture after incubation. In reaction mixtures with 50 µg LPS, 
normal antisera, and complement, residual hemolysis was negligible (table 
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3) ,whereas complement controls with antisera and VBS had a mean 37.5 C1 H50 
units. Thus in normal serum reaction mixtures with 50 µg of endotoxin, 
hemolytic levels were reduced to a negligible level. The control levels 
represent the complement hemolytic unit in all reaction mixtures prior to 
incubation. 
Chelated reaction mixtures and controls effected no hemolysis, due to 
++ the removal of Ca ions and negation of classical complement activity. 
However, the recalcification of chelated reaction mixtures and controls, 
prior to incubation with amboceptor, retained classical activity. The re-
action mixture with LPS had a mean 6.4% hemolysis (negligible C1H50 units), 
while the recalcified control had a measurement of 44.4 units (48.1%). 
The activated recalcified mixture had a significantly low titer of hemolytic 
complement activity, though slightly above the normal serum reaction mix-
ture. Hence, chelation with MgEGTA removed classic complement activity from 
serum reaction mixtures, which could be reactivated by saturation with Ca++. 
The small, almost insignificant, hemolytic levels of recalcified LPS-acti-
Table 3 
Residual Hemolytic Activity of Normal & Chelated Serum* 
Mixture 
Reaction for Hemolysis 
Mixture Hemolytic Estimation % 
Diln Vol. 
C', VBS, & antiserum 4.0 25.7% 
1:10 5.0 30.7% 
LPS,C', & antiserum 4.0 1. 9% 
5.0 1.4% 
Chelated C', & anti- 4.0 0 
serum 1:10 5.0 0 
LPS, chelated C', & 4.0 0 
antiserum 5.0 0 
Recalcified C', & 4.0 47.6% 
antiserum 1:10 5.0 48.6% 
Recalcified C', LPS 4.0 8.5% 
& antiserum 5.0 4.3% 
Neg = negligible 
* As explained in text 
Residual 
c'H50 
units 
32.4 
42.5 
39.3 
49.5 
Neg. 
Neg. 
~ 
...... 
vated reaction was due to LPS consumption of the six terminal components. 
This corroborates previous studies in which LPS of V. alcalescens and E. 
coli reacted with large amounts of the six terminal complement components 
in normal and chelated serum (Synderman et al., 1968; Gewurz et al., 1968; 
and Fine, 1974). This measurement of residual hemolytic complement was 
made as a control of the effect of chelation with MgEGTA. 
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DISCUSSION 
The objective of this study was to compare the ability of two 
LPS-activated complement pathways to effect chemotaxis of PMN leuko-
cytes. This was done by activating the classic and alternate pathways 
in one series of reactions, and comparing them to chelated reactions 
which exhibited the activity of the alternate pathway. This direct 
measurement of complement chemotactic factors has been reported to 
be the most significant assay of the use of terminal complement com-
ponents. Previous studies reported the ability of LPS to consume 
greater amounts of the six terminal complement components than zymosan, 
inulin, or immune complexes (Synderman et al., 1968, 1969; and Gewurz 
et al., 1968). However, classic complement activity generated by im-
mune complexes could not be compared to alternate pathway activity (LPS, 
inulin, and zymosan) in the production of C3a, C5a, and CSb-6-7, due to 
the inefficiency of measuring C1H50 units in these experiments. In the 
kinetics of complement hemolysis, only 10 to 20% of C3b and C5b are re-
tained on the red cell membrane for construction of the attack unit, and 
can not be used to determine active cleavage products in the fluid phase 
(Rapp & Boros, 1970; Kabat & Mayer, 1961; and Mayer, 1970). Thus, the 
data of this study has particular importance for the function of the al-
ternate pathway in the production of biologically active products. 
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The chemotaxis and hemolysis experiments do not directly measure 
or describe the molecular consequences of classical or alternate com-
plement activation, but they do provide evidence dependent on the ef-
ficiency of the two pathways to consume the six terminal complement 
components. There was a slight difference between the low levels of 
hemolysis in the normal reaction mixtures, but may have been the re-
sult of unused Cl, C2, and C4 in the latter. The ability of LPS-
activation of the alternate pathway to consume significantly large a-
mounts of C3 to C9 corroborates evidence of the ability of !· coli and 
V. alcalescens LPS to produce the same results (Synderman et al., 1968; 
and Fine, 1974). Classic complement pathway activation relies on the 
correct spacial arrangement of IgG for contact with Clq (IgG , n>l). 
n 
However, the ever-increasing number of alternate pathway activators re-
presents a more general and nonspecific complement activation that has 
been demonstrated in this study to equal the classic and alternate sys-
terns together. Thus, the alternate complement pathway equals the clas-
sic pathway in the efficiency of activation and consumption of the six 
terminal components. This could be due to the numerous repeating subu-
nits in the lipid A portion of LPS available for contact with IF of the 
properdin system. This reaction is analogous to IgG -Clq contact, but 
n 
does not require specificity such as the Clq-receptor in the Fe frac-
tion of immunoglobulins (Muller-Eberhard, 1975). The two pathways, thus, 
function as equal effector systems in producing biologically active prod-
ucts in nonspecific and specific reactions. 
Endotoxin has been shown to cause the directed migration of blood 
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leukocytes through the activation of a complement peptide, C5a (Synder-
man et al., 1968, 1969, 197la, and 1972; Shin et al., 1968, 1969; Gewurz 
et al., 1971; Kay & Austen, 1970). PMN leukocytes, monocytes, eosino-
phils, and basophilic leukocytes are attracted to this factor, which 
also possesses anaphylactic ability with C3a (Jensen et al., 1969). The 
inability of CS-deficient mice to hault bacterial infection following 
the primary lodgement of organisms is a further example of the impor-
tance of biologically active complement peptides participating in host 
defense mechanisms. These two minor complement peptides were also de-
termined to possess chemotactic activity for PMNs. 
Complement components C3a and C5a generated by either pathway were 
also identified as principle anaphyltoxins, which degranulate mast cells 
and basophils, cause increased vascular permeability, smooth muscle con-
traction, and the extravasation of fluids from vessels (Gewurz et al., 
1971; Hook et al., 1970; Dierich et al., 1973; Muller-Eberhard, 1975; and 
Ward, 1971). Many pathological features of endotoxin-complement reac-
tions in experimental animals are present in the Arthus phenomenon, and 
can be simulated by immune complexes (Jensen et al., 1969; and Stetson, 
1964). Thus, C3a and C5a function in both immune and innate reactions 
in host defense mechanisms by mediating the inflanunatory response. 
The in vitro activities of LPS-complement chemotaxis have been re-
lated to the in vivo inflanunatory effects caused by the experimental in-
jection of LPS and purified CSa. The injection of endotoxin causes a 
number of pathological occurences dependent on the function of a viable 
complement system (Thomas, 1954; Gewruz et al., 1970; Pearlman et al., 
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1963; and Mergenhagen et al., 1969). These reactions include local skin 
inflammation with intravascular coagulation, PMN accumulation, vasculi-
tis, and necrosis (Greisman, 1960; and Stetson, 1951). These reactions 
were mediated via principle biologically active peptides cleaved from 
LPS-activation of the alternate complement pathway (Mergenhagen et al., 
1973; and Gewurz et al., 1971), 
The chemotaxis experiments of this study corroborate previous data 
of the production of biologically active C5a in both classic and alter-
nate pathway in vitro systems, and suggest that the alternate pathway can 
produce in vivo chemotactic and anaphylactic factors in reactions equal 
to those produced with two functional complement pathways. The alter-
nate pathway could mediate an inflammatory response identical to classic 
complement amplification of an immune response, and preceed the latter 
in certain infections as a primary humeral defense mechanism. 
The presence of C3a, C5a, and C5b-6-7 in human pathological fluids, 
serum, and experimental vasculitis has indicated the ability. of comple-
ment chemotactic factors to mediate inflammation and the in vivo accumu-
lation of leukocytes in causing tissue destruction (Mergenhagen et al., 
1972; Muller-Eberhard, 1972a; and Ward, 1971). Phagocytosis of comple-
ment-tagged (C3b) particles by leukocytes results in degranulation of the 
leukocytes and release of proteolytic enzymes capable of causing connec-
tive tissue damage, extravasation of plasma, and Arthus vasculitis. ~ur­
therrnore, the attraction of PMNs to alternate pathway produced factors 
has been shown to cause selective enzyme release in the absence of spe-
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cific particles. It has also been found that if the PMN plasma membrane 
is perturbed sufficiently, pertubation, fusion, and extrusion of enzymes 
occurs through a process of reverse endocytosis (Goldstein et al., 1973). 
The interaction of C5a and the PMN membrane has caused the release of ly-
sozyme, S-glucuronidase, and microtubule assembly. In vivo, this is de-
pende~t on phagocytosis or adherence to complement opsonized particles 
(Goldstein et al., 1975). It is probable that the classic activation of 
complement can function as an effector of immune tissue destruction 
through the accumulation and degranulation of PMN leukocytes. In addi-
tion, the alternate pathway could also function in nonspecific tissue 
destruction that preceeds any immune involvement, and would act syner-
gistically with the latter, upon prolonged exposure, in tissues suscepti-
ble to damage by inflammatory products. 
Solid evidence for the role of the alternate pathway in disease, 
in the absence of classic pathway activation, is difficult to obtain due 
to the potential of classic generated C3b, which could react with Pa and 
bind P if deposited on a membrane (Gotze & Muller-Eberhard, 1976). How-
ever, in cases where the alternate pathway functions in tissue injury, 
it could act either as the principal complement effector, or produce bio-
logically active products with the classic pathway (Naff, 1972). The ana-
phylactic and chemotactic activities of C3a and C5a in initiating and sus-
taining inflammation are simultaneous with the opsonization of particles 
or membranes with C3b to facilitate adherence to the accumulating leuko-
cytes, and enhancing phagocytosis (Jensen, 1969). Thus, the presence of 
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a powerful complement activator, such as bacterial endotoxin, in either 
initial or prolonged exposure, could result in the continual production 
of inflammatory products. This tremendous inflammatory.response could 
mediate tissue destruction, and is of particular importance in tissues 
suceptible to damage from inflammation (Lepow, 1972; Synderman, 1972a; 
and Muller-Eberhard et al., 1973). These are reactions in which immuno-
globulin production would not necessarily be critical for optimum com-
plement activation and production of phlogistic products. 
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The interaction of endotoxin with complement, innately or in the 
presence of immunoglobulins to specific "O" antigens, may be implicated, 
partially, in the etiology of soft and hard periodontal tissue destruc-
tion. Low, but biologically significant levels of LPS have been demon-
strated in plaque as well as in Gram-negative bacteria isolated from plaque 
(Berglund et al., 1969; and Mergenhagen et al., 1961). Although the great-
er per centage of cultivable bacteria in the normal gingival crevice are 
Gram-positive rods and cocci (Actinomyces and Streptococcus species), Gram-
negative anaerobic rods and cocci (Veillonella, Fusobacterium, and Bactero-
ides) compose approximately 28% of the cultivable flora (Socransky, 1970). 
Veillonella species have been found to occur in subgingival plaque up to 
8% of the cultivable flora, while Gram-negative rods range from 6.5% to 
61.2% after sixteen days of growth (Stig et al., 1976). Thus, subgingi-
val plaque is a good source of bacterial endotoxin. 
Crevicular material and plaque extracts in clinically healthy in-
dividuals harbor factors chemotactic for PMNs that are heat labile 
at S6°C, and can induce experimental vasculitis (Hellden & Lindhe, 1973; 
Tempel et al., 1970; Egleberg, 1967; Kahnberg, 197S; Lindhe & Hellden, 
1972; and Miller et al., 197S), The additional finding of C3 and C4 in 
clinically healthy gingival crevices, and C3pa and CS in chronically in-
flanuned gingivae, indicates that complement is quite active in gingival 
inflanunation (Attstrom et al., 197S; and Shillitoe & Lehner, 1972). De-
complementation of Labrador Retrievers prior to topical application of 
plaque extracts failed to initiate vasculitis observed in the experi-
mental initial gingivitis in the control dogs (Kahnberg et al., 1976). 
The presence of endotoxin in the cell walls of Veillonella, Fusobacter-
ium, and Bacteroides species found in subgingival plaque could account for 
some of the complement activation in both initial gingivitis and chronic 
periodontal disease. 
Previous clinical studies have suggested a relationship between oral 
endotoxin levels and the severity of gingival inflanunation (Simon et al., 
1970, 1971, and 1969). The resultant tissue damage could be mediated via 
the complement cleavage of CS (Porter et al., 1971; Sarknes, 1966). In-
creases in the levels of endotoxin in crevicular exudate, dental plaque, 
and gingival tissue have been ~orrelated to the degree of clinical inflam-
mation in periodontal patients (Shapiro et al., 1972). Increasing gingi-
val index scores have also been shown to accompany increases in endotoxin-
containing Gram-negative bacterial cells in plaque, including Veillonella 
species (S to 2S%) (van Palenstein & Hoogeveen, 1976; and Johnson et al., 
1976). The potent ability of oral Veillonella endotoxins to activate com-
plement in vitro and generate significant chemotaxis can be related to in 
SS 
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vivo inflarmnation in periodontal tissues (Synderman et al., 1969, 1972a). 
v. alcalescens Cl is similar in the structure of its cell wall and lipo-
polysaccharide to the various oral strains under study (Mergenhagen et al., 
1969; Synderman et al.,. 1968; and Mergenhagen et al., 1961). The actual 
form of endotoxin in the sulcular environment is probably closer to that 
of a lysed cell wall fragment, rather than the purified soluble product. 
This study has demonstrated the ability of those LPS-containing cell wall 
fragments to activate complement chemotaxis in various quantities. Thus, 
the activity of the extracted LPS can be related to the cell wall particle. 
The data of this study is of special interest in acute periodontal in-
flaI!j11J,ation and soft tissue destruction. Initial acute gingivitis could 
occur through the interaction of endotoxin with complement in the absence 
of a significant titer of antibody. Through the mechanical irritation of 
plaque, calculus, and bacterial enzymes, endotoxin-containing cell wall 
particles could penetrate crevicular epithelium for immediate contact with 
complement components and activation of the alternate pathway. The data 
of the chemotaxis experiments emphasize the extent of this initial comple-
ment activation as being equal to an immune response, which would occur 
over a longer period of time (5 to 14 days), upon primary exposure of this 
antigen. The biological effects in causing vascular permeability, smooth 
muscle contraction, mast cell degranulation, and chemotaxis of PMNs and 
monocytes are relevent to the onset of periodontal inflarmnation. The sub-
sequent phagocytosis and metabolism of leukocytes would result in lysosomal 
release of enzymes, including cathepsins and collagenases (Cochrane, 1968). 
Thus, the products in plaque, rather than the organisms themselves, may in-
itiate a chain of molecular events resulting in the progressive destruc-
tion of supporting periodontal structures. 
The accumulation and degradation of leukocytes would cause initial 
tissue destruction, the breakdown of intracellular substances (desmosomes 
and hemidesmosomes), and the further penetration into gingival epithelium 
and lamina propria of endotoxin and other bacterial antigens. The latter 
has been demonstrated with purified LPS in experimental gingivitis, and 
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has been observed in gingival biopsies of patients with periodontal disease 
(Schwartz et al., 1972; Tempel et al., 1970; and Shapiro et al., 1972). 
The prolonged exposure of LPS and stimulation of immune mechanisms would 
not necessarily increase inflammatory products, according to the in vitro 
measurements of chemotaxis in the immune and non-immune systems. However, 
as the disease progresses, the environment becomes more favorable for an-
aerobic organisms, which includes the LPS-containing Gram-negative species. 
The accompanying increases in LPS lead to the further progression of perio-
dontal inflammation, but does not necessarily depend on immunoglobulin pro-
duction. Thus, the initial exposure of small amounts of endotoxin-contain-
ing particles are sufficient to activate complement and cause inflammation 
and tissue destruction. This cycle of LPS and antigen penetration, expo-
sure to immune and non-immune host defenses, and inflammation would become 
self-sustaining, and lead to the further progression of the disease process. 
In chronic periodontal inflammation, the large amounts of endotoxins 
found in pocket formation could be constantly activating complement through 
both pathways, and producing factors to act synergistically with lyrnphokines 
in the chemotactic attraction of monocytes and eosinophils (Kay et al.,1975). 
The resultant bone resorption accompanying chronic inflammation could also 
be influenced by complement activation (Synderman, 1972). The release of 
heparin from connective tissue mast cells in regions of alveolar bone 
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could cause bone resorption. Heparin had been shown to act synergistically 
with gingival tissue fragments in enhancing in vitro bone resorption (Gold-
haber, 1965, 1971). Lyososomal enzymes, derived from inflammatory leuko-
cytes, also have been shown to stimulate in vitro bone decalcification 
(Fell, et al., 1966). Lastly, endotoxin has been found to directly in-
hibit bone growth and stimulate chondroclast resorption in tissue culture 
(Hauseman, et al., 1970), Thus, endotoxin-complement generation of bio-
logically active products are probably responsible, in part, for perio-
dontal tissue destruction in acute and chronic inflammation through innate 
or immune mechanisms. 
The objectives of this study have been fulfilled: the chemotaxis in 
two complement pathways was studied with the alternate pathway solely, and 
was supported by a subline of evidence in residual hemolytic complement 
measurements; and this in vitro function has been related to possible in 
vivo effects of the production of phlogistic peptides. 
SUMMARY 
The cell wall and endotoxin extracted from Veillonella alcalescens 
activated· the alternate complement pathway and produced chemotactic fac-
tors for polymorphonuclear leukocytes. The purified endotoxin generated 
chemotactic activity from whole guinea pig serum in reactions equal to 
chemotaxis with one hundred fold greater amounts of cell wall material. 
Therefore, the major complement activating ability of 'Y..· alcalescens 
cell walls is due to the biologically active endotoxin. 
Lipopolysaccharide-activated complement measured in immune and non-
immune reaction mixtures showed no significant differences in the chemo-
taxis of PMNs between the alternate pathway, solely, and both active com-
plement pathways together. This establishes non-immune alternate path-
way activation as an equal biological effector to immune activation of 
the classic pathway in the production of factors which mediate the in-
flammatory response. 
Endotoxin-complement activation is significant in tissues suscep-
tible to damage by the inflammatory response. The continual presence 
and infiltration of Gram-negative bacteria and endotoxin in the healthy 
human gingival sulcus is a factor in the initiation of periodontal dis-
ease through alternate complement pathway activation, subsequent accumu-
lation and degradation of PMNs and monocytes, epithelial tissue destruc-
tion, and further antigen penetration to underlying lamina propria with 
immunocompetant cells. 
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